The Trump administration finalized agreements Dec. 19 with nine pharmaceutical manufacturers to offer U.S. patients prescription drug prices aligned with the lowest rates paid by other developed nations.
The companies — Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi — agreed to provide “most-favored-nation” pricing on various therapies, including treatments for cancer, Type 2 diabetes, rheumatoid arthritis, HIV, hepatitis B and C, and asthma. Medicaid programs in all 50 states will gain access to these pricing arrangements, according to a White House news release.
The agreements also include substantial discounts for direct-to-patient sales through TrumpRx. Examples include Sanofi’s blood thinner Plavix, reduced from $756 to $16; Gilead’s hepatitis C drug Epclusa, cut from $24,920 to $2,425; and Novartis’ multiple sclerosis drug Mayzent, lowered from $9,987 to $1,137. Insulin products from Sanofi will be priced at $35 for a one-month supply.
The nine companies will reinvest $150 billion into U.S. manufacturing and donate key active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve, the release said. Contributions will include 98.8 kilograms of albuterol from GSK, 6.5 tons of apixaban from Bristol Myers Squibb and 3.5 tons of ertapenem from Merck.
The announcement builds on earlier agreements the administration reached with Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk. Each company committed to most-favored-nation pricing and pledged significant investments in domestic manufacturing and research. The November deal with Lilly and Novo Nordisk marked a turning point, with both companies agreeing to cap monthly Medicare prices for their GLP-1 diabetes and obesity drugs at $245 beginning in 2026. They also committed to offering discounted cash prices through TrumpRx and applying the pricing model to all future products launched in the U.S.
